Virtual Library

Start Your Search

  • WCLC 2013

    15th World Conference on Lung Cancer

    Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.

    Presentation Date(s):  
    • October 27 - 30, 2013
    • Total Presentations: 2517

Filter Results:

Show Only Available Presentations

  • +

    P1.24 - Poster Session 1 - Clinical Care

    • Type: Poster Session
    • Track: Supportive Care
    • Presentations: 53
    • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
    • +

      P1.24-048 - Stage 1 results of a 2-stage phase II trial of single agent amrubicin in patients with previously treated thymic malignancies

      09:30 - 09:30  |  Author(s): H.A. Wakelee

      • Abstract

      Loading...

  • +

    P2.15 - Poster Session 2 - Thymoma

    • Type: Poster Session
    • Track: Thymoma & Other Thoracic Malignancies
    • Presentations: 8
    • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
    • +

      P2.15-003 - Gli1, Notch1 and CTNNB1 Expression by Automated Quantitative Immunofluorescence (AQUA) in a Thymic Malignancy Tissue Microarray (TMA)

      09:30 - 09:30  |  Author(s): J.W. Riess

      • Abstract

      Loading...

  • +

    P3.06 - Poster Session 3 - Prognostic and Predictive Biomarkers

    • Type: Poster Session
    • Track: Biology
    • Presentations: 53
    • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
    • +

      P3.06-003 - Correlative Analysis of Circulating Biomarkers from a Phase 1b/2 trial of Cabozantinib (C) with or without Erlotinib (E) in Patients (Pts) with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

      09:30 - 09:30  |  Author(s): S.K. Padda

      • Abstract

      Loading...

  • +

    P3.11 - Poster Session 3 - NSCLC Novel Therapies

    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 52
    • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
    • +

      P3.11-006 - Erlotinib (E) and Dovitinib (TKI258) (D) in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (NSCLC): A Significant Pharmacokinetic (PK) Interaction

      09:30 - 09:30  |  Author(s): M. Das

      • Abstract

      Loading...